The haematological malignancies include a diverse group of chronic and acute diseases which arise due to malignant transformation of blood-forming tissues.
They are a major cause of morbidity and death and are used extensively as model diseases for the study of malignant transformation and new drug development.
The Centre for Haemato-Oncology is one of the foremost research groups in the study of haematological malignancies in Europe. It comprises groups within Northern Institute for Cancer Research, Institute for Cell and Molecular Biosciences, Institute for Cellular Medicine and Clinical Haematology.
The Centre's work focuses on its strengths in the field of leukaemia and lymphoma research initiating high quality studies that delivers excellent benefit to patients.
Our primary areas of research are:
- Integration of Genetics into Clinical Trials - Prof Christine Harrison, Prof Anthony Moorman, Dr Lisa Russell, Dr Paul Sinclair
- The Newcastle Haematology Biobank - Prof Andy Hall
- Molecular genetics of leukaemia - Dr James Allan
- The pathogenesis of second malignant neoplasms after therapy - Dr James Allan
- Molecular Pharmacology of Childhood Leukaemia - Dr Julie Irving
- Oncogenic Fusion Genes - Prof Olaf Heidenreich
- Characterising and Targeting Leukaemia Stem Cells - Prof Josef Vormoor
- Molecular Pharmacology of Toposiomerase agents - Prof Caroline Austin, Dr Ian Cowell, Miss Kayleigh Smith, Mr Ka Cheong Lee
- Childhood Lymphoma - Dr Vikki Rand, Dr Chris Bacon
- Epigenetic Misregulation of Genes in Leukaemia - Dr Gordon Strathdee
- Successful Treatment of Chronic Myeloid Leukaemia - Prof Stephen O’Brien
- Development of Treatment Protocols in Resource Challenged countries - Prof Simon Bailey, Dr Roderick Skinner, Dr Peter Carey, Dr Kevin Windebank
- Improving Treatment of Multiple Myeloma - Prof Graham Jackson
- Dendritic cells in immunodeficiency and haematological malignancy - Prof Matthew Collin
- Treatment of Elderly Leukaemia Patients - Prof Stephen Proctor
- Therapeutic intervention in chronic lymphocytic leukaemia - Dr Elaine Willmore